CAMBRIDGE, England and BOSTON, March 18, 2014 /PRNewswire/ Linguamatics' sales showed strong growth and exceeded ten million dollars in 2013, it was announced today - outperforming the company's targeted growth and expected sales figures. The increased sales came from a boost in new customers and increased software licenses to existing customers in the pharmaceutical and healthcare sectors. This included 130 per cent growth in healthcare sales plus increased sales in professional services.
Access to the right knowledge at the right time is crucial for knowledge driven organizations such as those in healthcare and pharmaceuticals. Linguamatics software platform, I2E, uses natural language processing (NLP) to go beyond conventional search methods and understand the meaning of text. I2E identifies and extracts facts, assertions and relationships from unstructured text such as scientific literature, patents, clinical trials data, electronic health records (EHR), news feeds, social media and proprietary content in real-time and puts them into a structured format for further analysis to support key decision-making. I2E delivers dramatically improved speed to actionable insight, using computer algorithms to automatically mine, analyze and connect relevant knowledge buried in vast amounts of textual data and generate higher quality, targeted results.
Linguamatics' customers include 16 of the top 20 global pharmaceutical companies, the US Food and Drug Administration (FDA), leading US hospitals, cancer institutes and academic research centers.
Commenting on the company's performance in 2013, John M. Brimacombe, Executive Chairman of Linguamatics, said: "Our continued growth and success comes from our ability to respond to the demanding requirements of the pharmaceutical and healthcare industries to solve their big data problems. We're delivering an innovative and market-leading NLP platform to answer many difficult and high-value questions from genomics through to patient care. I'm excited about our future development plans and their potential impact on helping to bring drugs to market faster and improve patient outcomes."
Linguamatics is the world leader in deploying innovative natural language processing (NLP)-based text mining for high-value knowledge discovery and decision support. Linguamatics I2E is used by top commercial, academic and government organizations, including 16 of the top 20 global pharmaceutical companies, the US Food and Drug Administration (FDA) and leading US hospitals. I2E can be used to mine a wide variety of text resources, such as scientific literature, patents, Electronic Health Records (EHRs), clinical trials data, news feeds, social media and proprietary content. I2E can be deployed as an in-house enterprise system, or as Software-as-a-Service (SaaS) on the cloud.
Typical applications in pharmaceuticals, biotechnology, healthcare, government and other sectors include:
- Mapping gene-disease relationships and identifying potentially novel therapeutic targets
- Biomarker discovery
- Drug repurposing
- Drug safety
- Patent analysis
- Clinical trial site selection and study design
- Mining electronic medical records to improve prediction of health outcomes
- Clinical Trial matching
- Mining pathology reports
- Translational medicine
- Competitive intelligence
- Social media mining
- Sentiment analysis
Read more news from Linguamatics.